Please login to the form below
Abbott's paediatric HIV drug wins FDA approval
US-based pharmaceutical company Abbott wins FDA approval for its lower-strength protease-inhibitor Kaletra, which will be available in the US from November 2007
US-based pharmaceutical company Abbott has won FDA approval for its lower-strength protease-inhibitor Kaletra (lopinavir/ritonavir), which will be available in the US from November 2007.
The new lower-strength tablets are smaller in size than original Kaletra tablets and contain the same proven active ingredients as Abbott's Kaletra oral solution. The lower-strength Kaletra tablet is approved for children weighing 15 kg or more who are able to swallow the intact tablet.
Scott Brun, divisional vice-president of infectious diseases and renal development at Abbott's global pharmaceutical R&D arm, said: "HIV/AIDS continues to have a devastating impact globally, especially among the more than two million children living with the disease throughout the world. Abbott developed a lower-strength tablet formulation of Kaletra to give doctors an innovative treatment option to help curb the impact of HIV infection in children."
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Pfizer CEO pushes back COVID-19 vaccine submission to November
- Galapagos mid-stage trial failure raises concerns for Gilead deal
- The Truth about Doctors
- Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses
- Novartis scores CHMP backing for cholesterol drug Leqvio
- Novartis scores CHMP backing for cholesterol drug Leqvio
- Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
- FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- Vaccine developers call on FDA to offer clarity on COVID-19 trials
- The other side of … blood cancer
- COVID-19 – a catalyst for technology adoption in clinical trials
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
- The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
- The other side of … blood cancer
- To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
- COVID-19 – a catalyst for technology adoption in clinical trials
- As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...
Quick links
Infographics
